Anheuser-Busch InBev (BUD): Q2 normalized EPS $0.93 vs consensus of $1.03.
Revenues $10.59B vs reference base of $10.35B and consensus of $10.2B.
Organic sales +3.9% vs consensus of +3.7%.
Organic EBITDA +5.8% on a like-for-like basis to $3.895B, topping analyst estimates of $3.78B.
Normalized profit $1.5B vs $1.935B.
Profit $7.46B vs $1.94B (PR)